Retinal Drugs And Biologics Market: Global Industry Analysis 2012-2016 and Opportunity Assessment 2017-2027


Future Market Insights

$ 5000

The retinal wellbeing issue incorporate age-related macular degeneration, irresistible retinitis, diabetic retinopathy, macular edema, retinoblastoma, macular opening, retinoschisis, retinal degeneration, and uveitis. Diabetic retinopathy is another crucial retinal illness which is an aftereffect of complexities of diabetes. Diabetes harm the small retinal veins and blood or liquids begin to break out from the vessels. The treatment of retinal issue incorporate medical procedure and medicines.

Rising Cases of Optahlmic Disorders to Uplift Global Market Demand

  • The surging number of instances of ophthalmic issue because of age-related issues is the prime factor that adds to the development of the retinal medications and biologics market. The advancement of a few new items in types of medication discharging inserts and biologics attributable to the persistent efforts that are taken for the improvement and research of new treatment alternatives are adding to the market development.
  • The advancements in the biologics-Lucentis-in the field of ophthalmology have totally improved the treatment of the patients. But, the constrained accessibility of the biologics, harmful reactions of the biologics, stringent administrative guidelines that are related with biologics approval, and absence of awareness for biologics and successful medications inferable from the expanded cost may hinder the growth in the market.
  • Genetic retinal infections is the real reason behind the visual impairment. Macular degeneration, Diabetic Retinopathy is the significant and noticeable reason for visual impairment. Against VEGF intravitreal (IVT) injectable prescription is majorly used to treat retinal issue. Rising prescription regarding anti-VEGF foresee the development of the intravitreal (IVT) injectable. Numerous producers intends to create drugs that have anti-VEGF inhibitor, subsequently prompting an expansion in the demand regarding intravitreal (IVT) injectable.

Retina is a very sensitive and delicate part of human eye which is responsible for receiving and processing light to convert into neural signals and send to the brain for visual activity. The disorders related to retinal health include age-related macular degeneration, diabetic retinopathy, infectious retinitis, macular edema, macular hole, retinoblastoma, retinal degeneration, retinoschisis and uveitis etc. There are various types of retinal disorders but most of them cause visual symptoms. For instance, age-related macular degeneration (AMD), the most common retinal disease is associated with aging. It is a leading cause of blindness among people over the age of 50. Diabetic retinopathy is another major retinal disease which is a result of complications of diabetes. Diabetes damage the tiny blood vessels of retina and blood or fluids start to leak out from the vessels. The treatment of retinal disorders include surgery and medicines.

Retinal Drugs and Biologics Market: Drivers and Restraints

The key contributor to the growth of global retinal drugs and biologics market is globally rising incidences of ophthalmic disorders related to age. Emergence of various innovative products in forms of biologics and drug releasing implants as a result of research and development and continuous efforts to invent treatment alternatives are contributing to the market growth. Introduction of biologics such as Lucentis to the ophthalmology field has represented a true paradigm shift in the treatment of patients. Lucentis has been successful in preserving vision in 90% of wet age related macular degeneration. However, the availability of limited number of biologics, severe side effects of biologics, strict regulatory norms associated with the approval of biologics, inaccessibility to the effective drugs and biologics due to high costs may limit the market growth.

Retinal Drugs and Biologics Market: Segmentation

Global retinal drugs and biologics market has been segmented on the basis of types of conditions, types of therapies, distribution channels and region.

Based on types of conditions, the global retinal drugs and biologics market is segmented into:

  • Age related macular degeneration
  • Diabetic retinopathy
  • Ocular Inflammatory Disease (Uveitis)
  • Macular Hole

Based on the types of therapies, the global retinal drugs and biologics market is segmented into:

  • Surgery
  • Medicines
    • Intravitreal Injections
    • Medicines
      • Anti-VEGF Drugs
        • Ranibizumab
        • Bevacizumab
        • Aflibercept
      • Intravitreal Implant Releasing Steroids
        • Dexamethasone
        • Fluocinolone
  • Retinal Laser

Based on the distribution channels, the global Retinal Drugs and Biologics Market is segmented into:

  • Retail Pharmacies
  • Hospital Pharmacies
  • Specialty Ophthalmology Clinics

Retinal Drugs and Biologics Market: Overview

Global Retinal Drugs and Biologics market is highly fragmented with the presence of multiple players.Overall market is expected to report a sound growth as the epidemiologic studies have revealed that over 296 million people suffer from some type of retinal disease or condition globally, around 142 million people across the globe are impacted by age-related macular degeneration and approximately 105 million are affected by diabetic eye disease, these two diseases in combination are leading causes of vision loss globally.

Retinal Drugs and Biologics Market: Region-wise Outlook

Geographically, Retinal Drugs and Biologics  Market  is segmented into regions viz. North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific excluding Japan, Japan, Middle East and Africa. European countries have been witnessed highest incidence rates in case of retinal disorders followed by North America. The incidence rates of retinal diseases in Asia Pacific countries is comparatively less but it is increasing gradually, hence the market will show a gradual increase in this region. Diabetes also plays a significant role in retinal disease treatment market. The growing incidence rate of diabetes in developed countries due to sedentary life style and unhealthy habits is expected to fuel the market growth for retinal diseases drugs and biologics.

Retinal Drugs and Biologics Market: Key Players

Some of the players active in the global Retinal Drugs and Biologics Market include ALLERGAN, Alimera Sciences, AbbVie Inc., Janssen Biotech, Inc., Swedish Orphan Biovitrum, F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Genzyme Corporation, Genentech USA, Inc., OCULAR THERAPEUTIX, INC. and Bausch & Lomb Incorporated and UCBCares.

MRR.BIZ has been compiled in-depth market research data in the report after exhaustive primary and secondary research. Our team of able, experienced in-house analysts has collated the information through personal interviews and study of industry databases, journals, and reputable paid sources.

The report provides the following information:

  • Tailwinds and headwinds molding the market’s trajectory
  • Market segments based on products, technology, and applications
  • Prospects of each segment
  • Overall current and possible future size of the market
  • Growth pace of the market
  • Competitive landscape and key players’ strategies

The main aim of the report is to:

  • Enable key stakeholder’s in the market bet right on it
  • Understand the opportunities and pitfalls awaiting them
  • Assess the overall growth scope in the near term
  • Strategize effectively with respect to production and distribution

MRR.BIZ is a leading provider of strategic market research. Our vast repository consists research reports, data books, company profiles, and regional market data sheets. We regularly update the data and analysis of a wide-ranging products and services around the world. As readers, you will have access to the latest information on almost 300 industries and their sub-segments. Both large Fortune 500 companies and SMEs have found those useful. This is because we customize our offerings keeping in mind the specific requirements of our clients.